Evgen Pharma PLC (AIM:EVG) chief executive Huw Jones has said he anticipates being able to confirm the improved delivery of a newly formulated version of SFX-01, its lead asset.
His comments were made alongside an update on the progress of sulforaphane-based drug treatment that noted the completion of dosing of all three cohorts of its placebo-controlled, dose-escalating, randomised phase I/Ib clinical trial.
The clinical evaluation aims to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric-coated tablet formulation of SFX-01.
At the same time, researchers are also investigating how sulforaphane is released from SFX-01 and engages with molecular targets of interest.
As indicated previously, the data from the study is expected in the second quarter.
The new enteric-coated tablet formulation has been used to replace the previous prototype capsule formulation. It releases sulforaphane, which is found in broccoli, to a targeted part of the intestine, with the goals of predictable release and minimisation of gastrointestinal side effects.
The new formulation, if it performs as expected, will be suitable for large-scale trials and commercial supply.
“We anticipate that it will confirm improved delivery of SFX-01 with our new formulation,” said Evgen CEO Jones in a statement. “In addition, it will demonstrate further how sulforaphane engages with key molecular targets as we expand into new indications in oncology and neurodevelopmental disorders.”